A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise

Simply Wall St.06-10 01:30

Intellia Therapeutics (NTLA) is back in focus after reporting strong Phase 3 data for lonvoguran ziclumeran in hereditary angioedema, outlining regulatory submission plans, and pairing the update with...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642943604?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-10 01:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642943604","market":"us","top_or_hot":-1,"title":"A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise","media":"Simply Wall St.","content":"<div>\n<p>Intellia Therapeutics (NTLA) is back in focus after reporting strong Phase 3 data for lonvoguran ziclumeran in hereditary angioedema, outlining regulatory submission plans, and pairing the update with...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-after-phase-3\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-10 01:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-after-phase-3><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intellia Therapeutics (NTLA) is back in focus after reporting strong Phase 3 data for lonvoguran ziclumeran in hereditary angioedema, outlining regulatory submission plans, and pairing the update with...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-after-phase-3\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169589451.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-after-phase-3","article_id":"2642943604","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-after-phase-3","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2642943604","pubTimestamp":1781026252,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Intellia Therapeutics (NTLA) is back in focus after reporting strong Phase 3 data for lonvoguran ziclumeran in hereditary angioedema, outlining regulatory submission plans, and pairing the update with an upsized equity raise.\nSee our latest analysis for Intellia Therapeutics.\nDespite a modest 1-day share price decline of 0.37% to US$13.49 and a softer 30-day share price return of 4.26% down, the year-to-date share price return of 46.47% and 1-year total shareholder return of 62.92% suggest...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","BK4535":"淡马锡持仓","BK4215":"住宅房地产投资信托","EQR":"资产住宅公司","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","BK4588":"碎股","HAE":"美国血液技术","NTLA":"Intellia Therapeutics Inc","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4585":"ETF&股票定投概念","BK4198":"医疗保健用品","BK4556":"基因编辑","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","BK4139":"生物科技","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD"},"translate_title":"第三阶段HAE成功和股权融资后Intellia Therapeutics(NTLA)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQR":1.5,"NTLA":1.5,"HAE":1.5},"content_text":"Intellia Therapeutics (NTLA) is back in focus after reporting strong Phase 3 data for lonvoguran ziclumeran in hereditary angioedema, outlining regulatory submission plans, and pairing the update with an upsized equity raise. See our latest analysis for Intellia Therapeutics. Despite a modest 1-day share price decline of 0.37% to US$13.49 and a softer 30-day share price return of 4.26% down, the year-to-date share price return of 46.47% and 1-year total shareholder return of 62.92% suggest momentum has picked up after earlier multi year total shareholder return declines. If Intellia’s update has you thinking more broadly about genomic medicine and AI driven drug development, it could be worth scanning 39 healthcare AI stocks So with Intellia’s share price still far below some analyst targets, yet backed by fresh Phase 3 data, cash through at least 2028 and rising attention on CRISPR, is the stock mispriced or already reflecting future growth? AdvertisementMost Popular Narrative: 49.3% Undervalued Analysts following Intellia see a fair value of $26.63 per share, compared with the last close at $13.49, and anchor that view on aggressive growth and profitability assumptions filtered through a 7.14% discount rate.  The analysts have a consensus price target of $26.63 for Intellia Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $847.4 million, earnings will come to $46.7 million, and it would be trading on a PE ratio of 120.0x, assuming you use a discount rate of 7.1%.  Read the complete narrative. Want to see what justifies nearly doubling the current share price in this narrative? The crux is a sharp swing from sizeable losses to positive earnings, paired with rapid revenue expansion and a rich future earnings multiple more often associated with established growth stars. Curious which specific growth and margin paths are baked into that view, and how they balance against execution risk and dilution assumptions? The full narrative lays those building blocks out in detail. Result: Fair Value of $26.63 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this upside story can crack if late stage trials stumble or if high development costs and equity raises weigh more heavily on future shareholder returns. Find out about the key risks to this Intellia Therapeutics narrative. Another View: Rich Multiples Versus Fair Value Signal Analysts’ fair value of $26.63 paints Intellia as 49.3% undervalued, yet the current P/S of 28.5x looks expensive compared with both the US Biotechs industry at 10.5x and a fair ratio of 0.1x. That gap points to meaningful valuation risk, so which signal do you trust? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:NTLA P/S Ratio as at Jun 2026Next Steps If this mix of optimism and concern feels familiar, act while the information is fresh and take time to weigh both sides for yourself with the 2 key rewards and 1 important warning sign. Looking for more investment ideas? Do not stop at one stock story. Broaden your watchlist with clear themes so you are not relying on a single outcome or sector. Use the Simply Wall Street Screener to uncover fresh opportunities that match how you like to invest, before the crowd shifts attention and prices move away from you.  Target possible higher upside potential by reviewing 23 elite penny stocks with strong financials that pair smaller market caps with more robust financial profiles than many peers. Refine your hunt for value by filtering through the 47 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet. Prioritise resilience and support more peace of mind by focusing on 63 resilient stocks with low risk scores that score well on financial health and lower risk indicators.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642943604","isCrawlerRequest":true}